Bacterial Whole Genome Sequencing (WGS) – Illumina Platform in UAE | 2500 AED | 2026 DHA Guidelines

1. What is bacterial whole genome sequencing, and how does the Illumina platform work?

Bacterial whole genome sequencing (WGS) decodes the complete DNA blueprint of a bacterial isolate by fragmenting its genome into millions of short reads, sequencing them in parallel on the Illumina platform, and computationally reassembling the reads against a curated reference database. This process identifies every gene present — including those conferring antibiotic resistance, virulence factors, and metabolic pathways — with base-pair-level accuracy. The resulting data enables your physician to select targeted antimicrobial therapy, avoiding broad-spectrum empiric treatments that contribute to resistance. The Illumina platform is globally recognized as the gold standard for clinical bacterial genomics due to its unmatched read accuracy (>99.9%) and high throughput capacity.

2. Why is Illumina-based WGS superior to traditional culture-based identification methods?

Illumina-based WGS surpasses traditional culture methods by providing culture-independent, comprehensive genomic data within a single assay, detecting slow-growing, fastidious, and non-culturable organisms that conventional microbiology would completely miss. Traditional culture relies on viable organisms growing on selective media — a process that can fail for up to 60% of clinically relevant bacteria. WGS bypasses this limitation entirely, working directly from extracted DNA. Furthermore, phenotypic susceptibility testing provides only qualitative sensitivity results, whereas WGS identifies the precise genetic mechanism of resistance (e.g., specific beta-lactamase variants, efflux pump mutations), enabling more nuanced therapeutic decisions and supporting antimicrobial stewardship programs across UAE healthcare facilities.

3. What are the clinical applications of bacterial genome analysis, and how will my results be reported?

Bacterial genome analysis serves multiple critical clinical functions including definitive pathogen identification, comprehensive antimicrobial resistance profiling, virulence factor characterization, and molecular epidemiological typing for infection control and outbreak investigation. Your results will be delivered as a structured clinical report containing: (1) species-level taxonomic identification with confidence scoring, (2) a curated list of detected antimicrobial resistance genes correlated with expected phenotypic resistance patterns, (3) virulence gene inventory with clinical significance annotations, (4) multi-locus sequence typing (MLST) for epidemiological tracking, and (5) a plain-language clinical interpretation summary suitable for sharing with your treating physician. The raw sequencing data (FASTQ files) and assembled genome are also available upon request for academic or research purposes, in compliance with UAE PDPL data privacy regulations.